Ocular manifestations of giant cell arteritis

References

• Weyand CM, Goronzy JJ. Medium-and large-vessel vasculitis. N Engl J Med. 2003 Jul 10;349(2):160–169.
   PubMed Web of Science ®Google Scholar
• Chacko JG, Chacko JA, Salter MW. Review of giant cell arteritis. Saudi J Ophthalmol. 2015 Jan 1;29(1):48–52.
   PubMed Web of Science ®Google Scholar
• Gonzalez‐Gay MA, Vazquez‐Rodriguez TR, Lopez‐Diaz MJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Care Res. 2009 Oct 15;61(10):1454–1461.
   Web of Science ®Google Scholar
• Chen JJ, Leavitt JA, Fang C, et al. Evaluating the incidence of arteritic ischemic optic neuropathy and other causes of vision loss from giant cell arteritis. Ophthalmology. 2016 Sep 1;123(9):1999–2003.
   PubMed Web of Science ®Google Scholar
• Hayreh SS. Ophthalmic features of giant cell arteritis. Baillieres Clin Rheumatol. 1991 Dec 1;5(3):431–459.
   PubMedGoogle Scholar
• Weyand CM, Liao YJ, Goronzy JJ. The immunopathology of giant cell arteritis: diagnostic and therapeutic implications. J Neuroophthalmol. 2012 Sep;32(3):259.
   PubMed Web of Science ®Google Scholar
• González-Gay MA, García-Porrúa C, Llorca J, et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore). 2000 Sep;79(5):283–292.
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol. 1998 Apr 1;125(4):509–520.
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Dejaco C, Matteson EL, et al. Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA. 2016 Jun 14;315(22):2442–2458.
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Podhajsky PA, Zimmerman B. Occult giant cell arteritis: ocular manifestations. Am J Ophthalmol. 1998 Apr 1;125(4):521–526.
   PubMed Web of Science ®Google Scholar
• Aiello PD, Trautmann JC, McPhee TJ, et al. Visual prognosis in giant cell arteritis. Ophthalmology. 1993 Apr 1;100(4):550–555.
   PubMed Web of Science ®Google Scholar
• Cid MC, Font C, Oristrell J, et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum. 1998 Jan 1;41(1):26–32.
   PubMed Web of Science ®Google Scholar
• Ness T, Bley TA, Schmidt WA, et al. The diagnosis and treatment of giant cell arteritis. Dtsch Arztebl Int. 2013 May;110(21):376.
   PubMed Web of Science ®Google Scholar
• Chandran AK, Udayakumar PD, Crowson CS, et al. The incidence of giant cell arteritis in Olmsted County, Minnesota, over a 60-year period 1950–2009. Scand J Rheumatol. 2015 May 4;44(3):215–218.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ, et al. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore). 2005 Sep 1;84(5):269–276.
   PubMed Web of Science ®Google Scholar
• Smith CA, Fidler WJ, Pinals RS. The epidemiology of giant cell arteritis. Report of a ten‐year study in Shelby County, Tennessee. Arthritis Rheum. 1983 Oct;26(10):1214–1219.
   PubMedGoogle Scholar
• Haugeberg GL, Paulsen PQ, Bie RB. Temporal arteritis in Vest Agder County in southern Norway: incidence and clinical findings. J Rheumatol. 2000 Nov;27(11):2624–2627.
   PubMed Web of Science ®Google Scholar
• Pipinos II, Hopp R, Edwards WD, et al. Giant-cell temporal arteritis in a 17-year-old male. J Vasc Surg. 2006 May 1;43(5):1053–1055.
   PubMed Web of Science ®Google Scholar
• Bas-Lando M, Breuer GS, Berkun Y, et al. The incidence of giant cell arteritis in Jerusalem over a 25-year period: annual and seasonal fluctuations. Clin Exp Rheumatol. 2007 Jan 1;25(1 Suppl 44):S15–7.
   PubMed Web of Science ®Google Scholar
• Frohman L, Wong AB, Matheos K, et al. New developments in giant cell arteritis. Surv Ophthalmol. 2016 Jul 1;61(4):400–421.
   PubMed Web of Science ®Google Scholar
• Wagner AD, Gérard HC, Fresemann T, et al. Detection of Chlamydia pneumoniae in giant cell vasculitis and correlation with the topographic arrangement of tissue‐infiltrating dendritic cells. Arthritis Rheum. 2000 Jul 1;43(7):1543–1551.
   PubMedGoogle Scholar
• Bhatt AS, Manzo VE, Pedamallu CS, et al. Brief report: in search of a candidate pathogen for giant cell arteritis: sequencing‐based characterization of the giant cell arteritis microbiome. Arthritis Rheum. 2014 Jul 1;66(7):1939–1944.
   Web of Science ®Google Scholar
• Powers JF, Bedri S, Hussein S, et al. High prevalence of herpes simplex virus DNA in temporal arteritis biopsy specimens. Am J Clin Pathol. 2005 Feb 1;123(2):261–264.
   PubMed Web of Science ®Google Scholar
• Alvarez-Lafuente R, Fernandez-Gutierrez B, Jover JA, et al. Human parvovirus B19, varicella zoster virus, and human herpes virus 6 in temporal artery biopsy specimens of patients with giant cell arteritis: analysis with quantitative real time polymerase chain reaction. Ann Rheum Dis. 2005 May 1;64(5):780–782.
   PubMed Web of Science ®Google Scholar
• Helweg‐Larsen J, Tarp B, Obel N, et al. No evidence of parvovirus B19, Chlamydia pneumoniae or human herpes virus infection in temporal artery biopsies in patients with giant cell arteritis. Rheumatology. 2002 Apr 1;41(4):445–449.
   PubMed Web of Science ®Google Scholar
• Gilden D, White T, Khmeleva N, et al. Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis. Neurology. 2015 May 12; 84(19):1948–1955.
   PubMed Web of Science ®Google Scholar
• Nagel MA, White T, Khmeleva N, et al. Analysis of varicella-zoster virus in temporal arteries biopsy positive and negative for giant cell arteritis. JAMA Neurol. 2015 Nov 1;72(11):1281–1287.
   PubMed Web of Science ®Google Scholar
• Buckingham EM, Foley MA, Grose C, et al. Identification of herpes zoster–associated temporal arteritis among cases of giant cell arteritis. Am J Ophthalmol. 2018 Mar;1(187):51–60.
   Google Scholar
• Muratore F, Croci S, Tamagnini I, et al. No detection of varicella-zoster virus in temporal arteries of patients with giant cell arteritis. Semin Arthritis Rheum. 2017 Oct 1;47(2):235–240.
   PubMed Web of Science ®Google Scholar
• Ing EB, Ing R, Liu X, et al. Does herpes zoster predispose to giant cell arteritis: a geo-epidemiologic study. Clin Ophthalmol. 2018;12:113.
   PubMed Web of Science ®Google Scholar
• England BR, Mikuls TR, Xie F, et al. Herpes zoster as a risk factor for incident giant cell arteritis. Arthritis Rheum. 2017 Dec;69(12):2351–2358.
   Web of Science ®Google Scholar
• Hunder GG, Bloch DA, Michel BA, et al. The American college of rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990 Aug 1;33(8):1122–1128.
   PubMed Web of Science ®Google Scholar
• Kiel JW. The ocular circulation. In Colloquium series on integrated systems physiology: from molecule to function. Morgan & Claypool Life Sciences 2011 Jan 20;3(1):1–81. .
   Google Scholar
• Hayreh SS. Orbital vascular anatomy. Eye. 2006 Oct;20(10):1130.
   PubMed Web of Science ®Google Scholar
• Danesh-Meyer H, Savino PJ, Gamble GG. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology. 2005 Jun 1;112(6):1098–1103.
   PubMed Web of Science ®Google Scholar
• Justice J, Lehmann RP. Cilioretinal arteries: a study based on review of stereo fundus photographs and fluorescein angiographic findings. Arch Ophthalmol. 1976 Aug 1;94(8):1355–1358.
   PubMedGoogle Scholar
• Almarzouqi SJ, Morgan ML, Lee AG. Treatment of giant cell arteritis. Curr Opin Ophthalmol. 2015 Nov 1;26(6):469–475.
   PubMed Web of Science ®Google Scholar
• Fraser JA, Weyand CM, Newman NJ, et al. The treatment of giant cell arteritis. Rev Neurol Dis. 2008;5(3):140.
   PubMedGoogle Scholar
• Brack A, Martinez‐Taboada V, Stanson A, et al. Disease pattern in cranial and large‐vessel giant cell arteritis. Arthritis Rheum. 1999 Feb;42(2):311–317.
   PubMed Web of Science ®Google Scholar
• Blockmans D, Ceuninck LD, Vanderschueren S, et al. Repetitive 18F‐fluorodeoxyglucose positron emission tomography in giant cell arteritis: A prospective study of 35 patients. Arthritis Care Res. 2006 Feb 15;55(1):131–137.
   Web of Science ®Google Scholar
• Prieto-González S, Arguis P, García-Martínez A, et al. Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. Ann Rheum Dis. 2012 Jul 1;71(7):1170–1176.
   PubMed Web of Science ®Google Scholar
• Guevara M, Kollipara CS. Recent advances in giant cell arteritis. Curr Rheumatol Rep. 2018 May 1;20(5):25.
   PubMed Web of Science ®Google Scholar
• Zhang H, Watanabe R, Berry GJ, et al. Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. Proc Natl Acad Sci U S A. 2017 Feb 7;114(6):E970–9.
   PubMed Web of Science ®Google Scholar
• Pryshchep O, Ma-Krupa W, Younge BR, et al. Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation. 2008 Sep 16;118(12):1276–1284.
   PubMed Web of Science ®Google Scholar
• Dejaco C, Brouwer E, Mason JC, et al. Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. Nat Rev Rheumatol. 2017 Oct;13(10):578.
   PubMed Web of Science ®Google Scholar
• Sultan H, Smith SV, Lee AG, et al. Pathologic markers determining prognosis in patients with treated or healing giant cell arteritis. Am J Ophthalmol. 2018 Jun 8.193:45-53.
   Web of Science ®Google Scholar
• Ly KH, Régent A, Molina E, et al. Neurotrophins are expressed in giant cell arteritis lesions and may contribute to vascular remodeling. Arthritis Res Ther. 2014 Dec;16(6):487.
   PubMed Web of Science ®Google Scholar
• Kaiser M, Weyand CM, Björnsson J, et al. Platelet‐derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum. 1998 Apr;41(4):623–633.
   PubMedGoogle Scholar
• Rana AQ, Saeed U, Khan OA, et al. Giant cell arteritis or tension-type headache? A differential diagnostic dilemma. J Neurosci Rural Pract. 2014 Oct;5(4):409.
   PubMedGoogle Scholar
• Rahman W, Rahman FZ. Giant cell (temporal) arteritis: an overview and update. Sur Ophthalmol. 2005 Sep 1;50(5):415–428.
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Podhajsky PA, Raman R, et al. Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol. 1997 Mar 1;123(3):285–296.
   PubMed Web of Science ®Google Scholar
• Graham E, Holland A, Avery A, et al. Prognosis in giant-cell arteritis. Br Med J (Clin Res Ed). 1981 Jan 24;282(6260):269–271.
   PubMed Web of Science ®Google Scholar
• Baldursson Ó, Steinsson K, Björnsson J, et al. Giant cell arteritis in Iceland. Arthritis Rheum. 1994 Jul 1;37(7):1007–1012.
   PubMedGoogle Scholar
• Font C, Cid MC, Coll-Vinent B, et al. Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis. Br J Rheumatol. 1997 Feb 1;36(2):251–254.
   PubMedGoogle Scholar
• Vodopivec I, Rizzo JF III. Ophthalmic manifestations of giant cell arteritis. Rheumatology. 2018 Feb 1;57(suppl_2):ii63–72.
   PubMed Web of Science ®Google Scholar
• Diego M, Margo CE. Postural vision loss in giant cell arteritis. J Neuroophthalmol. 1998 Jun;18(2):124–126.
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Zimmerman MB, Podhajsky P, et al. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol. 1994 May 1;117(5):603–624.
   PubMed Web of Science ®Google Scholar
• Nesher G, Berkun Y, Mates M, et al. Risk factors for cranial ischemic complications in giant cell arteritis. Medicine (Baltimore). 2004 Mar 1;83(2):114–122.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cimino L, Macchioni P, et al. Risk factors for visual loss in an Italian population‐based cohort of patients with giant cell arteritis. Arthritis Care Res. 2005 Apr 15;53(2):293–297.
   Web of Science ®Google Scholar
• Ross M, Bursztyn L, Superstein R, et al. Multiple cranial nerve palsies in giant cell arteritis. J Neuroophthalmol. 2017 Dec 1;37(4):398–400.
   PubMed Web of Science ®Google Scholar
• Mehler MF, Rabinowich L. The clinical neuro-ophthalmologic spectrum of temporal arteritis. Am J Med. 1988 Dec 1;85(6):839–844.
   PubMed Web of Science ®Google Scholar
• Thurtell MJ, Longmuir RA. Third nerve palsy as the initial manifestation of giant cell arteritis. J Neuroophthalmol. 2014 Sep 1;34(3):243–245.
   PubMed Web of Science ®Google Scholar
• Davies GE, Shakir RA. Giant cell arteritis presenting as oculomotor nerve palsy with pupillary dilatation. Postgrad Med J. 1994 Apr 1;70(822):298–299.
   PubMed Web of Science ®Google Scholar
• Bayar SA, Gokmen O, Pinarci EY, et al. Corneal endothelial decompensation and ocular hypotony in a case with temporal arteritis. J Neuroophthalmol. 2012 Dec 1;32(4):385.
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Pitzalis C, Panayi GS. Inflammation of the uveal tract as a presenting feature of temporal arteritis. Ann Rheum Dis. 1989 Nov;48(11):964.
   PubMed Web of Science ®Google Scholar
• Ferrari L, Preziosa P, Barcella V, et al. Subacute visual loss and bilateral fixed mydriasis: an atypical case of giant cell arteritis. Neurol Sci. 2014 Aug 1;35(8):1309.
   PubMed Web of Science ®Google Scholar
• Nesher GI, Nesher RO, Rozenman YA, et al. Visual hallucinations in giant cell arteritis: association with visual loss. J Rheumatol. 2001 Sep 1;28(9):2046–2048.
   PubMed Web of Science ®Google Scholar
• Hayreh SS. Acute retinal arterial occlusive disorders. Prog Retin Eye Res. 2011 Sep 1;30(5):359–394.
   PubMed Web of Science ®Google Scholar
• Coupal DJ, Patel AD. Siegrist streaks in giant cell arteritis. J Neuroophthalmol. 2003 Dec 1;23(4):272–273.
   PubMed Web of Science ®Google Scholar
• Murchison AP, Gilbert ME, Bilyk JR, et al. Validity of the American college of rheumatology criteria for the diagnosis of giant cell arteritis. Am J Ophthalmol. 2012 Oct 1;154(4):722–729.
   PubMed Web of Science ®Google Scholar
• Oh LJ, Wong E, Gill AJ, et al. Value of temporal artery biopsy length in diagnosing giant cell arteritis. ANZ J Surg. 2018 Mar;88(3):191–195.
   PubMed Web of Science ®Google Scholar
• Luqmani R, Lee E, Singh S, et al. The role of ultrasound compared to biopsy of temporal arteries in the diagnosis and treatment of giant cell arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health Technol Assess. 2016;20:90.
   Web of Science ®Google Scholar
• Karassa FB, Matsagas MI, Schmidt WA, et al. Meta-analysis: test performance of ultrasonography for giant-cell arteritis. Ann Intern Med. 2005 Mar 1;142(5):359–369.
   PubMed Web of Science ®Google Scholar
• Chambers WA, Bernardino VB. Specimen length in temporal artery biopsies. J Neuroophthalmol. 1988 Jun 1;8(2):121–126.
   Web of Science ®Google Scholar
• Mahr A, Saba M, Kambouchner M, et al. Temporal artery biopsy for diagnosing giant cell arteritis: the longer, the better? Ann Rheum Dis. 2006 Jun 1;65(6):826–828.
   PubMed Web of Science ®Google Scholar
• Breuer GS, Nesher R, Nesher G. Effect of biopsy length on the rate of positive temporal artery biopsies. Clin Exp Rheumatol. 2009 Jan 1;27(1):S10.
   PubMed Web of Science ®Google Scholar
• Taylor-Gjevre R, Vo M, Shukla D, et al. Temporal artery biopsy for giant cell arteritis. J Rheumatol. 2005 Jul 1;32(7):1279–1282.
   PubMed Web of Science ®Google Scholar
• Sharma NS, Ooi JL, McGarity BH, et al. The length of superficial temporal artery biopsies. ANZ J Surg. 2007 Jun 1;77(6):437–439.
   PubMed Web of Science ®Google Scholar
• Nuenninghoff DM, Hunder GG, Christianson TJ, et al. Incidence and predictors of large‐artery complication (aortic aneurysm, aortic dissection, and/or large‐artery stenosis) in patients with giant cell arteritis: a population‐based study over 50 years. Arthritis Rheum. 2003 Dec 1;48(12):3522–3531.
   PubMedGoogle Scholar
• Francis CE. Giant cell arteritis. J Neuroophthalmol. 2016 Mar 1;36(1):e2–4.
   PubMed Web of Science ®Google Scholar
• Boyev LR, Miller NR, Green WR. Efficacy of unilateral versus bilateral temporal artery biopsies for the diagnosis of giant cell arteritis. Am J Ophthalmol. 1999 Aug 1;128(2):211–215.
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology. 2010 Apr 5;49(8):1594–1597.
   PubMed Web of Science ®Google Scholar
• Bowling K, Rait J, Atkinson J, et al. Temporal artery biopsy in the diagnosis of giant cell arteritis: does the end justify the means? Ann Med Surg. 2017 Aug;1(20):1–5.
   Google Scholar
• Slavin ML, Barondes MJ. Visual loss caused by choroidal ischemia preceding anterior ischemic optic neuropathy in giant cell arteritis. Am J Ophthalmol. 1994 Jan 1;117(1):81–86.
   PubMed Web of Science ®Google Scholar
• Schmidt WA. Role of ultrasound in the understanding and management of vasculitis. Ther Adv Musculoskelet Dis. 2014 Apr;6(2):39–47.
   PubMedGoogle Scholar
• Schäfer VS, Juche A, Ramiro S, et al. Ultrasound cut-off values for intima-media thickness of temporal, facial and axillary arteries in giant cell arteritis. Rheumatology. 2017 Jul 3;56(9):1479–1483.
   PubMed Web of Science ®Google Scholar
• Khan A, Dasgupta B. Imaging in giant cell arteritis. Curr Rheumatol Rep. 2015 Aug 1;17(8):52.
   PubMed Web of Science ®Google Scholar
• Klink T, Geiger J, Both M, et al. Giant cell arteritis: diagnostic accuracy of MR imaging of superficial cranial arteries in initial diagnosis—results from a multicenter trial. Radiology. 2014 Aug 6;273(3):844–852.
   PubMed Web of Science ®Google Scholar
• de Boysson H, Lambert M, Liozon E, et al. Giant-cell arteritis without cranial manifestations: working diagnosis of a distinct disease pattern. Medicine (Baltimore). 2016 Jun;95(26):e3818.
   Web of Science ®Google Scholar
• Foroozan R, Danesh-Meyer H, Savino PJ, et al. Thrombocytosis in patients with biopsy-proven giant cell arteritis. Ophthalmology. 2002 Jul 1;109(7):1267–1271.
   PubMed Web of Science ®Google Scholar
• Parikh M, Miller NR, Lee AG, et al. Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology. 2006 Oct 1;113(10):1842–1845.
   PubMed Web of Science ®Google Scholar
• Kermani TA, Schmidt J, Crowson CS, et al. Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum. 2012 Jun 1;41(6):866–871.
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Zimmerman B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology. 2003 Jun 1;110(6):1204–1215.
   PubMed Web of Science ®Google Scholar
• Nesher G, Sonnenblick M, Friedlander Y. Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol. 1994 Jul;21(7):1283–1286.
   PubMed Web of Science ®Google Scholar
• Strehl C, Bijlsma JW, de Wit M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016 Jun 1;75(6):952–957.
   PubMed Web of Science ®Google Scholar
• Hočevar A, Rotar Ž, Tomšič M. Does leflunomide have a role in giant cell arteritis? An open-label study. Clin Rheumatol. 2018 Aug;6:1–6.
   Google Scholar
• Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377:317–328.
   PubMed Web of Science ®Google Scholar
• Walker UA. Letter to the editor. N Engl J Med. 2017 Oct 12;377(15):1494–1495. Trial of Tocilizumab in Giant-Cell Arteritis. Stone JH, Klearman M, Collinson N.
   PubMedGoogle Scholar
• Buono LM, Foroozan R, De Virgiliis M, et al. Heparin therapy in giant cell arteritis. Br J Ophthalmol. 2004 Feb 1;88(2):298–301.
   PubMed Web of Science ®Google Scholar
• Broder MS, Sarsour K, Chang E, et al. Corticosteroid-related adverse events in patients with giant cell arteritis: a claims-based analysis. Semin Arthritis Rheum. 2016 Oct 1;46(2):246–252.
   PubMed Web of Science ®Google Scholar